Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar. Methods We analysed 40 127 adult fluoroquinolone primary‐suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004–2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k‐means was primary, validated by k‐modes and hierarchical clustering. Cluster number (k = 2–15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides ( n = 39 948) and amoxicillin ( n = 16 310). Results At PT level, silhouette and Calinski–Harabasz indices were optimal at two clusters (Davies–Bouldin at three; silhouette 0.560), separating a multi‐system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs . 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs . 5.3% (macrolides) and 3.9% (amoxicillin). Conclusions Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi‐system adverse‐event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis‐generating.

Authors

Institutions

Publication Details

Journal
British Journal of Clinical Pharmacology
Published
2026-09-30
DOI
https://doi.org/10.1002/bcp.70853
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

Niaz Chalabianloo, Sheikh Shaugat Abdullah, Kamran Sedig, Flory Tsobo Muanda
British Journal of Clinical Pharmacology
Pharmacovigilance and Adverse Drug Reactions
article

Unsupervised machine learning for multi‐system adverse event pattern detection in pharmacovigilance: A proof‐of‐concept analysis of fluoroquinolone reports in FAERS

Niaz Chalabianloo, Sheikh Shaugat Abdullah, Kamran Sedig, Flory Tsobo Muanda
article en

Abstract

Aims Traditional pharmacovigilance detects single drug–event associations but cannot readily characterize multi‐system adverse‐event patterns such as fluoroquinolone‐associated disability. We evaluated unsupervised machine learning for this purpose, using fluoroquinolones as an exemplar. Methods We analysed 40 127 adult fluoroquinolone primary‐suspect reports from the FDA Adverse Event Reporting System (FAERS, 2004–2025). Events were encoded as binary MedDRA Preferred Term (PT) and System Organ Class matrices; seriousness and outcome were excluded from clustering and used only post hoc. Multiple correspondence analysis with k‐means was primary, validated by k‐modes and hierarchical clustering. Cluster number (k = 2–15) was assessed by internal validity indices with bootstrap stability. Comparators were macrolides ( n = 39 948) and amoxicillin ( n = 16 310). Results At PT level, silhouette and Calinski–Harabasz indices were optimal at two clusters (Davies–Bouldin at three; silhouette 0.560), separating a multi‐system cluster (4072 reports; 10.1%) enriched for neuropsychiatric, musculoskeletal and sensory terms (lifts: memory impairment 8.6, muscle atrophy 8.3, dry eye 7.8). Excluding seriousness and outcome left the cluster essentially unchanged (91.4% retained; κ 0.95), indicating definition by event topology, not case severity; independent algorithms recovered the same subgroup across granularities. Post hoc, the cluster was disproportionately disabling (43.0% vs . 11.7%). The fixed signature classified 14.9% of fluoroquinolone reports vs . 5.3% (macrolides) and 3.9% (amoxicillin). Conclusions Unsupervised clustering of FAERS data identified, without prior clinical input, a reproducible multi‐system adverse‐event pattern among fluoroquinolone reports, potentially supporting the feasibility of unsupervised exploratory pattern detection in pharmacovigilance. Given the limitations of spontaneous reporting databases, the findings are strictly hypothesis‐generating.

British Journal of Clinical Pharmacology
Western University (CA), Lawson Health Research Institute (CA), London Health Sciences Centre (CA), MacEwan University (CA)
Quality Education
Openalex Percentile: Top 13%
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.